Long term use of AstraZeneca’s blood thinner Brilinta has been recommended as a cost-effective option in the UK for treating patients after a heart attack.
A Welsh stem cell company founded by a Nobel prize winner has signed a partnership deal with Daiichi Sankyo.
U.S. government scientists have raised questions about the potential risks to patients of heart attacks and blood clots from Abbott Laboratories’ novel coronary stent that dissolves after it is implanted. […]
Novo Nordisk and AstraZeneca, two drugmakers whose financial outlooks disappointed investors last month, are both hoping for a boost in the coming weeks from results of two closely watched clinical […]
(Reuters Health) – After surviving a heart attack or severe blockage of blood flow to the heart, optimistic people are more likely to make healthy lifestyle changes and less likely […]
A restaurant industry trade group is suing New York City’s Board of Health to stop it from enforcing a new rule requiring many chain restaurants to post warnings on menu […]
An experimental heart drug from GlaxoSmithKline failed to work as hoped in the first part of a large clinical trial, the company said on Tuesday, dealing a blow to its […]
A new blood test might help doctors figure out faster whether someone’s having a heart attack. The test reliably told doctors which patients were not having heart attacks after only […]
Express Scripts Holding Co, the largest manager of prescription drug plans for U.S. employers and health plans, said it has reached deals to cover two costly new cholesterol drugs and […]
A biotech company founded by a Nobel prize winner has won the go-ahead from European regulators to begin the application process for conditional marketing authorization of a stem cell-based regenerative […]